Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2017 | Pages:
131 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Endometriosis - Pipeline Review, H2 2017 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Endometriosis - Pipeline Review, H2 2017, provides an overview of the Endometriosis (Women's Health) pipeline landscape. Endometriosis is an often painful disorder in which tissue that normally lines the inside of uterus (endometrium) grows outside uterus (endometrial implant). Symptoms include pelvic pain, menstrual cramps, inflammation, infertility and abnormal bleeding. Risk factors age, uterine abnormalities, history of pelvic infection and family history. Treatment includes NSAIDs, birth control pills and progestins. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Endometriosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Endometriosis (Women's Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Endometriosis (Women's Health) pipeline guide also reviews of key players involved in therapeutic development for Endometriosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 2, 9, 7, 1, 14, 5 and 4 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 4 and 3 molecules, respectively. Endometriosis (Women's Health) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Endometriosis (Women's Health). - The pipeline guide reviews pipeline therapeutics for Endometriosis (Women's Health) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Endometriosis (Women's Health) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Endometriosis (Women's Health) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Endometriosis (Women's Health) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Endometriosis (Women's Health). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Endometriosis (Women's Health) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 5 Introduction 7 Global Markets Direct Report Coverage 7 Endometriosis - Overview 8 Endometriosis - Therapeutics Development 9 Pipeline Overview 9 Pipeline by Companies 10 Pipeline by Universities/Institutes 13 Products under Development by Companies 14 Products under Development by Universities/Institutes 17 Endometriosis - Therapeutics Assessment 18 Assessment by Target 18 Assessment by Mechanism of Action 21 Assessment by Route of Administration 24 Assessment by Molecule Type 26 Endometriosis - Companies Involved in Therapeutics Development 28 AbbVie Inc 28 Addex Therapeutics Ltd 28 APAvadis Biotechnologies Srl 29 Astellas Pharma Inc 29 Bayer AG 30 ElexoPharm GmbH 30 EndoCeutics Inc 31 Enteris BioPharma Inc 31 Evotec AG 32 Forendo Pharma Ltd 32 Kissei Pharmaceutical Co Ltd 33 Lipicard Technologies Ltd 33 Luye Pharma Group Ltd 33 Nippon Shinyaku Co Ltd 34 Ogeda SA 34 Philogen SpA 35 Repros Therapeutics Inc 35 SK Chemicals Co Ltd 35 Takeda Pharmaceutical Co Ltd 36 ValiRx Plc 36 Viramal Ltd 37 Endometriosis - Drug Profiles 38 acolbifene hydrochloride + GnRH Agonist + prasterone - Drug Profile 38 ADX-68692 - Drug Profile 39 BAY-1128688 - Drug Profile 40 BAY-1158061 - Drug Profile 41 BAY-1817080 - Drug Profile 42 BAY-1834845 - Drug Profile 43 danazol - Drug Profile 44 Drug 1 for Endometriosis - Drug Profile 45 Drug 2 for Endometriosis - Drug Profile 46 Drug 3 for Endometriosis - Drug Profile 47 Drug 4 for Endometriosis - Drug Profile 48 Drug for Endometriosis - Drug Profile 49 Drug to Antagonize P2X3 for Endometriosis - Drug Profile 50 Drug to Inhibit C-Jun for Endometriosis - Drug Profile 51 Drugs for Endometriosis and Uterine Fibroids - Drug Profile 52 EC-313 - Drug Profile 53 elagolix sodium - Drug Profile 54 fezolinetant - Drug Profile 60 FP-5677 - Drug Profile 63 goserelin ER - Drug Profile 64 KLH-2109 - Drug Profile 65 leuprolide acetate - Drug Profile 67 LT-6121 - Drug Profile 68 MIA-602 - Drug Profile 69 NHP-07 - Drug Profile 70 NS-580 - Drug Profile 71 opigolix - Drug Profile 72 Peptides for Endometriosis and Hepatic Tumor - Drug Profile 73 Peptides to Inhibit Aminopeptidase A for Endometriosis, Neuroblastoma and Hepatic (Liver) Tumor - Drug Profile 74 PGL-2001 - Drug Profile 75 progesterone - Drug Profile 76 Recombinant Protein for Endometriosis, Ovarian Hyperstimulation Syndrome and Polycystic Ovarian Syndrome - Drug Profile 77 relugolix - Drug Profile 78 SKI-2670 - Drug Profile 84 Small Molecule to Antagonize FSH Receptor and LH Receptor for Women's Health - Drug Profile 85 Small Molecules to Antagonize GnRH for Endometriosis, Male Health, Oncology and Uterine Fibroids - Drug Profile 86 Small Molecules to Antagonize Prostanoid EP2 and EP4 Receptors for Endometriosis - Drug Profile 87 Small Molecules to Inhibit 17 Beta-HSD1 for Endometriosis - Drug Profile 88 Small Molecules to Inhibit 17 Beta-Hydroxysteroid Dehydrogenase Type1 for Endometriosis and Estrogen Dependent Cancers - Drug Profile 89 Small Molecules to Inhibit CD147 for Immunology, Oncology, Endometriosis and Arthritis - Drug Profile 90 Small Molecules to Inhibit HSD17B1 for Endometriosis - Drug Profile 91 SR-16234 - Drug Profile 92 Stem Cell Therapy for Asherman's Syndrome and Endometrial Atrophy - Drug Profile 93 Synthetic Peptide to Antagonize GPR54 for Womens Health, Male Health and Oncology - Drug Profile 94 telapristone acetate - Drug Profile 95 tetravil - Drug Profile 104 TOT-206 - Drug Profile 106 triptorelin acetate ER - Drug Profile 107 VAL-301 - Drug Profile 108 vilaprisan - Drug Profile 109 VPE-001 - Drug Profile 111 Endometriosis - Dormant Projects 112 Endometriosis - Discontinued Products 114 Endometriosis - Product Development Milestones 115 Featured News & Press Releases 115 Appendix 127 Methodology 127 Coverage 127 Secondary Research 127 Primary Research 127 Expert Panel Validation 127 Contact Us 127 Disclaimer 128
List of Tables
Number of Products under Development for Endometriosis, H2 2017 Number of Products under Development by Companies, H2 2017 Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Development by Universities/Institutes, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Products under Development by Companies, H2 2017 (Contd..2), H2 2017 Products under Development by Universities/Institutes, H2 2017 Number of Products by Stage and Target, H2 2017 Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Endometriosis - Pipeline by AbbVie Inc, H2 2017 Endometriosis - Pipeline by Addex Therapeutics Ltd, H2 2017 Endometriosis - Pipeline by APAvadis Biotechnologies Srl, H2 2017 Endometriosis - Pipeline by Astellas Pharma Inc, H2 2017 Endometriosis - Pipeline by Bayer AG, H2 2017 Endometriosis - Pipeline by ElexoPharm GmbH, H2 2017 Endometriosis - Pipeline by EndoCeutics Inc, H2 2017 Endometriosis - Pipeline by Enteris BioPharma Inc, H2 2017 Endometriosis - Pipeline by Evotec AG, H2 2017 Endometriosis - Pipeline by Forendo Pharma Ltd, H2 2017 Endometriosis - Pipeline by Kissei Pharmaceutical Co Ltd, H2 2017 Endometriosis - Pipeline by Lipicard Technologies Ltd, H2 2017 Endometriosis - Pipeline by Luye Pharma Group Ltd, H2 2017 Endometriosis - Pipeline by Nippon Shinyaku Co Ltd, H2 2017 Endometriosis - Pipeline by Ogeda SA, H2 2017 Endometriosis - Pipeline by Philogen SpA, H2 2017 Endometriosis - Pipeline by Repros Therapeutics Inc, H2 2017 Endometriosis - Pipeline by SK Chemicals Co Ltd, H2 2017 Endometriosis - Pipeline by Takeda Pharmaceutical Co Ltd, H2 2017 Endometriosis - Pipeline by ValiRx Plc, H2 2017 Endometriosis - Pipeline by Viramal Ltd, H2 2017 Endometriosis - Dormant Projects, H2 2017 Endometriosis - Dormant Projects, H2 2017 (Contd..1), H2 2017 Endometriosis - Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
